Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  International Business Machines Corporation    IBM

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

International Business Machines Corp. : Memorial Sloan-Kettering Cancer Center, IBM to Collaborate in Applying Watson Technology to Help Oncologists

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2012 | 03:35pm CEST

New York City - 22 Mar 2012: Memorial Sloan-Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide medical professionals with improved access to current and comprehensive cancer data and practices. The resulting decision support tool will help doctors everywhere create individualized cancer diagnostic and treatment recommendations for their patients based on current evidence.

The initiative will combine the computational power of IBM Watson and its natural language processing ability with MSKCC's clinical knowledge, existing molecular and genomic data and vast repository of cancer case histories, in order to create an outcome and evidence-based decision support system. The goal is to give oncologists located anywhere the ability to obtain detailed diagnostic and treatment options based on updated research that will help them decide how best to care for an individual patient.

The IBM Watson system gained fame by beating human contestants on the television quiz show Jeopardy! It can interpret queries in natural language and uses statistical analysis, advanced analytics and a powerful array of processors to search millions of pages in seconds and deliver evidence-based statistically-ranked responses.

MSKCC's world-renowned oncologists will assist in developing IBM Watson to use a patient's medical information and synthesize a vast array of continuously updated and vetted treatment guidelines, published research and insights gleaned from the deep experience of MSKCC clinicians to provide an individualized recommendation to physicians. The tool will also provide users with a detailed record of the data and evidence used to reach the recommendations.

The need for such an advanced technology arises from the steadily increasing complexity of oncology treatment. Cancers are the second most common cause of death in the U.S., second only to heart disease, and the American Cancer Society projects that 1.6 million new cancer cases will be diagnosed in the U.S. this year* with outcomes varying widely across the country. Cancer is not one disease but some hundreds of sub-types, each with a different genetic fingerprint. Significant discoveries in molecular biology and genetics in the past two decades have delivered new insights into cancer biology and strategies for targeting specific molecular alterations in tumors, but these advances have also ratcheted up the complexity of diagnosing and treating each case. Oncologists and physicians who do not specialize in specific sub-types of cancer face a significant challenge in keeping up with the magnitude of rapidly changing information.

 "The combination of transformational technologies found in Watson with our cancer analytics and decision-making process has the potential to revolutionize the accessibility of information for the treatment of cancer in communities across the country and around the world," said MSKCC President and CEO Craig B. Thompson. "Consistent with our mission, the vision is to help better identify and personalize cancer therapies for each individual patient, no matter where that patient may be receiving care. We also expect tremendous new research opportunities to emerge from this collaboration."

"Memorial Sloan-Kettering's evidence-based clinical approach, scientific acumen, and vast database make it the ideal partner in this ambitious project," said Dr. Martin Kohn, chief medical scientist, IBM. "Cancer care is profoundly complex with continuous clinical and scientific advancements to consider. This field of clinical information, given its importance on both a human and economic level, is exactly the type of grand challenge IBM Watson can help address."

"This comprehensive, evidence-based approach will profoundly enhance cancer care by accelerating the dissemination of practice-changing research at an unprecedented pace," said Dr. Mark G. Kris, Chief, Thoracic Oncology Service at MSKCC and one of the clinicians leading the development effort. He noted that 85 percent of patients with cancer are not treated at specialized medical centers and it can take years for the latest developments in oncology to reach all practice settings.

Development work is already underway for the first applications, which include lung, breast and prostate cancers. The objective is to begin piloting the solutions to a select group of oncologists in late 2012, with wider distribution planned for late 2013. This collaboration complements an earlier announcement by IBM and WellPoint that the parties will focus on putting Watson to work on oncology solutions. 

About Memorial Sloan-Kettering Cancer Center

Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to www.mskcc.org

*American Cancer Society, Cancer Facts and Figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.

distributed by

This press release was issued by IBM - International Business Machines Corporation and was initially posted at http://www-03.ibm.com/press/us/en/pressrelease/37235.wss . It was distributed, unedited and unaltered, by noodls on 2012-03-22 15:27:46 PM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTERNATIONAL BUSINESS MAC
04:21pINTERNATIONAL BUSINESS MACHINES : IBM boosts support of cloud-native capabilitie..
AQ
02:22pINTERNATIONAL BUSINESS MACHINES : University of Michigan outdoes IBM with world`..
AQ
01:27pINTERNATIONAL BUSINESS MACHINES : Artificial Intelligence-Powered Sugar.IQ Diabe..
AQ
08:15aIoT in Banking and Finance Services Market Growing at CAGR of +52% by 2023 &n..
AQ
12:16aINTERNATIONAL BUSINESS MACHINES : Artificial Intelligence-Powered Sugar.IQ(TM) D..
AQ
06/22INTERNATIONAL BUSINESS MACHINES : U.S. Patents Awarded to Inventors in Tennessee..
AQ
06/22INTERNATIONAL BUSINESS MACHINES : U.S. Patents Awarded to Inventors in Vermont (..
AQ
06/22INTERNATIONAL BUSINESS MACHINES : IBM Support Services
AQ
06/22Hortonworks plays balancing act in the cloud
AQ
06/22INTERNATIONAL BUSINESS MACHINES : IBM launches PowerAI Enterprise
AQ
More news
News from SeekingAlpha
06/21DIGITAL REALTY : The One Tech Company Everyone Should Have In Their Portfolio 
06/21BLOCKCHAIN ETFS : Why You Should Consider BLOK Before All Others 
06/20Domo Adds A Scary Provision To Its Revised IPO Filing; Regardless Of Price, I.. 
06/20Box +3.1% on IBM agreement, high volume 
06/20Domo Readies Plans For $189 Million IPO 
Financials ($)
Sales 2018 80 813 M
EBIT 2018 14 413 M
Net income 2018 10 812 M
Debt 2018 31 885 M
Yield 2018 4,34%
P/E ratio 2018 12,12
P/E ratio 2019 11,55
EV / Sales 2018 2,00x
EV / Sales 2019 1,97x
Capitalization 130 B
Chart INTERNATIONAL BUSINESS MAC
Duration : Period :
International Business Mac Technical Analysis Chart | IBM | US4592001014 | 4-Traders
Technical analysis trends INTERNATIONAL BUSINESS MAC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 26
Average target price 168 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Virginia M. Rometty Chairman, President & Chief Executive Officer
James J. Kavanaugh Chief Financial Officer & Senior Vice President
John E. Kelly Senior VP-Cognitive Solutions & Research
Martin Jetter SVP-Global Technology Services
Sidney Taurel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INTERNATIONAL BUSINESS MACHINES CORPORATION-7.93%129 691
ACCENTURE4.27%102 656
TATA CONSULTANCY SERVICES34.00%102 057
AUTOMATIC DATA PROCESSING18.69%61 272
VMWARE, INC.19.70%60 972
COGNIZANT TECHNOLOGY SOLUTIONS11.52%46 110